Product Images Simvastatin

This appears to be a medicine label for Simvastatin tablets, USP indicating its usual adult dosage and storage conditions. The label also displays the manufacturer's details and cautions the user to keep it out of the reach of children.*

This is a description of Simvastatin Tablets, USP, a prescription medication used in adults to help lower cholesterol levels. The tablets are film-coated and contain 20mg of simvastatin. The dosage information is included in an accompanying insert. This medication is manufactured by Biocon Pharma Inc. and distributed in original containers by PuraCap Caribe. It should be stored between 20 to 25°C and kept out of reach of children. The output also contains a code that indicates the manufacturing date and other details.*

This is a description of a prescription drug called Simvastatin. It comes in the form of film-coated tablets with each tablet containing 40 mg of Simvastatin USP. The drug is dispensed in a unit-of-use container and should be stored between 20 to 25°C (68 to 77°F). The accompanying insert provides complete dosage information. The medication is manufactured by Biocon Pharma Inc. and PuraCap Caribe.*

Simvastatin Tablets, USP is a medication used for lowering cholesterol and triglycerides in certain people by reducing the amounts of these substances in the blood. Each container consists of 90 film-coated tablets, with each tablet containing 5mg of simvastatin. It is recommended to store the medication at a temperature between 20 to 25°C (68 to 77°F) and should be kept out of the reach of children. The instruction insert should be followed for complete dosage information. This medication is manufactured for Biocon Pharma Inc., Iselin, NJ 08830-3009 USA, and manufactured by PuraCap Caribe, Dorado, PR 00646 USA.*

This text appears to be a label for a medication called Simvastatin. It provides information on the dosage, storage, and manufacturer of the medication, as well as a caution to keep it out of reach of children. There is also reference to a controlled room temperature.*

The text provides information related to the results of a chemical assay that might represent inhibitors like erythromycin, HIV, nefazodone, clarithromycin, and Ketoconazole, except for results with propranolol. It mentions the term Simvastatin acid, which is referred to the p-hydroxyacid of Simvastatin. The text also talks about the amount of grapefruit juice used in two studies on Simvastatin pharmacokinetics in single and double-strength doses. It provides information about the administration of grapefruit juice and Simvastatin in these studies. However, the text lacks context and coherence.*

This is a table showing the adverse reactions reported from patients treated with Simvastatin versus Placebo in 45 cases. The table shows the percentage of patients that reported experiencing various disorders or conditions, which are categorized System wise. Adverse reactions that were greater than 2% and were more common amongst those treated with Simvastatin have been included in the table. The adverse reactions include edema/swelling, abdominal pain, atrial fibrillation, constipation, gastritis, diabetes mellitus, myalgia, headache, insomnia, vertigo, bronchitis, sinusitis, eczema, and urinary tract infection.*

Simvastatin is a medication used in clinical settings, with warnings and precautions noted. Dosages and potential side effects are listed. Additional information regarding the medication is not available.*

This text provides a table containing a list of drug interactions associated with an increased risk of MyopathyRhabdomyolysis. It includes a list of interacting agents with prescribing recommendations for patients. It also includes specific instructions for Chinese patients and specific drugs to avoid exceeding certain dosages. Additionally, the text provides precautions for patients with HOFH and advises them to avoid grapefruit juice. The last line of text seems to be scrambled and does not make sense.*